Deep Track Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Deep Track Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$136M	Buy	6,999,025 +590,162	+9%	+$10.7M	1.98%	20
2026 Q1	$119M	Buy	6,408,863 +1,798,792	+39%	+$29.8M	1.95%	16
2025 Q4	$60.8M	Buy	+4,610,071	New	+$54.4M	1.08%	25
2023 Q3	–	Sell	-108,450	Closed	-$5.53M	–	69
2023 Q2	$5.53M	Buy	+108,450	New	+$2.92M	0.26%	49

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Deep Track Capital's MLTX Position: Q2 2026 in Review

Deep Track Capital increased its MoonLake Immunotherapeutics (MLTX) stake by 9.2% in Q2 2026, buying an estimated $10.7M and bringing the position to 6,999,025 shares worth $136M. The position accounts for 1.98% of the portfolio, ranked #20.

Deep Track Capital first reported a position in MLTX in Q2 2023 and has held it in 4 quarters since. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Deep Track Capital held 6,999,025 shares of MoonLake Immunotherapeutics worth $136M as of Q2 2026.
Deep Track Capital bought 590,162 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $10.7M.
MoonLake Immunotherapeutics made up 1.98% of Deep Track Capital's portfolio in Q2 2026, its #20 holding.
Deep Track Capital first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 4 quarters since.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.